The Japanese Ministry of Health, Labor, and Welfare, or MHLW, has granted marketing authorization for Altuviiio, a first-in-class, high-sustained factor VIII replacement therapy, Sanofi announced. Altuviiio is indicated for control of bleeding tendency in patients with hemophilia A factor VIII deficiency. Altuviiio was also recently approved by the Taiwan Food and Drug Administration for treatment of adults and children with hemophilia A on August 31, Sanofi noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNY:
- MacroGenics, Aventis mutually terminate Royalty Purchase Agreement
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- First Wave (NASDAQ:FWBI) Skyrockets on Sanofi Licensing Deal
- First Wave BioPharma licenses Sanofi’s Capeserod for gastrointestinal disorders
- Sanofi price target raised to EUR 117 from EUR 111 at Guggenheim